Many across the country, including those in Texas, take medication. Whether over-the-counter or prescribed, individuals often turn to pharmaceuticals in hopes of effectively treating a medical condition. To entice the consuming public to take their product, most drug companies market their goods a successful way to treat specific ailments. Unfortunately, sometimes false claims are made or dangerous side effects are not disclosed, putting consumers at risk of harm.
A class-action lawsuit is in its early stages stemming from a drug company's false advertising. According to the complaint, the drug Anatabloc was made and marketed by Star Scientific, Rock Creek Pharmaceuticals, and GNC Holdings as a successful way to treat excessive inflammation associated with arthritis, traumatic brain injuries, diabetes, multiple sclerosis, and Alzheimer's disease. However, the lawsuit claims these claims have not been proven by clinical trials and the FDA has not approved the drug for its claimed purposes. Anatabloc was also promoted by former Virginia Gov. Robert McDonnell and his wife, who have both since been indicted on criminal bribery charges.
Though there does not appear to be any injuries related to the use of Anatabloc, the fact remains that defective drugs and harmful drugs are a sad presence in America's pharmaceutical market. These drugs can cause serious patient injury that may be irreparable. Victims may suffer from a worsened condition, permanent disability, or even death.
Those who are harmed by a defective or otherwise dangerous drug should consider seeking legal assistance. An attorney will be able to advise the victim as to what legal actions would be in his or her best interest. If the decision is made to move forward on a class action claim, then the attorney will do everything in his or her power to impose pharmaceutical liability on the parties responsible for the harm caused. In addition to providing compensation to victims, a class action lawsuit punishes errant companies, deterring them from being negligent in the future.
